Bioventus Inc (BVS)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR...

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations...

Form SD - Specialized disclosure report

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bioventus Reports First Quarter Financial Results

Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share...

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical...

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”...

Form ARS - Annual Report to Security Holders